Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Proto-Oncogene Proteins B-raf | 17 | 2021 | 1922 | 2.880 |
Why?
|
Drug Resistance, Neoplasm | 21 | 2022 | 5197 | 2.530 |
Why?
|
Colorectal Neoplasms | 26 | 2022 | 6497 | 2.520 |
Why?
|
MAP Kinase Kinase 1 | 5 | 2020 | 353 | 2.420 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 12 | 2022 | 1667 | 2.350 |
Why?
|
MAP Kinase Signaling System | 9 | 2019 | 1588 | 1.940 |
Why?
|
Protein Kinase Inhibitors | 19 | 2021 | 5405 | 1.910 |
Why?
|
Gastrointestinal Neoplasms | 6 | 2020 | 991 | 1.640 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 6 | 2018 | 603 | 1.190 |
Why?
|
Mutation | 30 | 2022 | 29262 | 1.170 |
Why?
|
raf Kinases | 2 | 2019 | 121 | 1.150 |
Why?
|
DNA, Neoplasm | 7 | 2019 | 1782 | 1.090 |
Why?
|
Gene Amplification | 6 | 2020 | 1087 | 1.000 |
Why?
|
Antineoplastic Agents | 13 | 2021 | 13714 | 0.910 |
Why?
|
Neoplasms | 15 | 2022 | 20172 | 0.870 |
Why?
|
Acetonitriles | 1 | 2021 | 50 | 0.840 |
Why?
|
ras Proteins | 7 | 2019 | 1116 | 0.790 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2021 | 11253 | 0.740 |
Why?
|
Benzimidazoles | 3 | 2014 | 882 | 0.610 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 996 | 0.610 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 605 | 0.590 |
Why?
|
Sulfonamides | 4 | 2013 | 1938 | 0.580 |
Why?
|
Medulloblastoma | 3 | 2008 | 715 | 0.580 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 749 | 0.580 |
Why?
|
Pyrimidines | 5 | 2021 | 2950 | 0.570 |
Why?
|
Pyrimidinones | 4 | 2020 | 351 | 0.550 |
Why?
|
Molecular Targeted Therapy | 9 | 2021 | 2878 | 0.530 |
Why?
|
Cell Line, Tumor | 18 | 2022 | 16959 | 0.520 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2021 | 199 | 0.500 |
Why?
|
Piperazines | 2 | 2021 | 2532 | 0.480 |
Why?
|
Pyridones | 4 | 2020 | 664 | 0.470 |
Why?
|
bcl-X Protein | 2 | 2013 | 405 | 0.450 |
Why?
|
Carcinoma, Pancreatic Ductal | 4 | 2021 | 1481 | 0.450 |
Why?
|
MAP Kinase Kinase Kinases | 2 | 2014 | 275 | 0.450 |
Why?
|
Oximes | 3 | 2020 | 317 | 0.450 |
Why?
|
Rectal Neoplasms | 4 | 2021 | 1117 | 0.430 |
Why?
|
Pyridines | 2 | 2021 | 2862 | 0.430 |
Why?
|
Aniline Compounds | 2 | 2013 | 953 | 0.420 |
Why?
|
Pancreatic Neoplasms | 7 | 2021 | 4930 | 0.410 |
Why?
|
Stomach Neoplasms | 2 | 2020 | 1214 | 0.410 |
Why?
|
Imidazoles | 4 | 2020 | 1268 | 0.400 |
Why?
|
Cerebellar Neoplasms | 2 | 2008 | 601 | 0.390 |
Why?
|
Esophageal Neoplasms | 2 | 2020 | 1449 | 0.390 |
Why?
|
Multiprotein Complexes | 2 | 2013 | 1162 | 0.380 |
Why?
|
Cholangiocarcinoma | 3 | 2021 | 516 | 0.370 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2019 | 3714 | 0.340 |
Why?
|
Humans | 77 | 2022 | 708843 | 0.340 |
Why?
|
Genes, ras | 1 | 2011 | 719 | 0.330 |
Why?
|
Oncogene Protein p21(ras) | 2 | 2019 | 88 | 0.330 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 4865 | 0.320 |
Why?
|
Feedback | 2 | 2022 | 747 | 0.320 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2008 | 270 | 0.320 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2013 | 2118 | 0.310 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3708 | 0.310 |
Why?
|
STAT3 Transcription Factor | 1 | 2011 | 895 | 0.310 |
Why?
|
Indoles | 2 | 2013 | 1857 | 0.310 |
Why?
|
Sterols | 1 | 2006 | 67 | 0.300 |
Why?
|
Signal Transduction | 11 | 2022 | 23950 | 0.300 |
Why?
|
Precancerous Conditions | 1 | 2011 | 964 | 0.260 |
Why?
|
Bile Duct Neoplasms | 2 | 2021 | 571 | 0.250 |
Why?
|
Mice, Nude | 6 | 2018 | 3859 | 0.230 |
Why?
|
Mice | 19 | 2022 | 80876 | 0.230 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 248 | 0.220 |
Why?
|
Neoplasm Metastasis | 4 | 2021 | 5112 | 0.220 |
Why?
|
Heterozygote | 1 | 2008 | 2780 | 0.220 |
Why?
|
Receptors, Cell Surface | 3 | 2009 | 2913 | 0.210 |
Why?
|
Lung Neoplasms | 4 | 2021 | 12183 | 0.210 |
Why?
|
Microsatellite Repeats | 2 | 2021 | 807 | 0.210 |
Why?
|
Basal Cell Nevus Syndrome | 1 | 2001 | 43 | 0.210 |
Why?
|
Animals | 26 | 2022 | 170486 | 0.210 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2011 | 3006 | 0.210 |
Why?
|
Neoadjuvant Therapy | 3 | 2021 | 2561 | 0.210 |
Why?
|
DNA Mismatch Repair | 2 | 2021 | 408 | 0.200 |
Why?
|
Papillomavirus Infections | 2 | 2022 | 1470 | 0.200 |
Why?
|
Hematologic Tests | 1 | 2021 | 232 | 0.200 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4044 | 0.190 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2020 | 2668 | 0.190 |
Why?
|
Survival Rate | 5 | 2020 | 13202 | 0.190 |
Why?
|
Melanoma | 2 | 2017 | 5194 | 0.190 |
Why?
|
RNA Editing | 1 | 2020 | 161 | 0.180 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 220 | 0.180 |
Why?
|
Retinoblastoma Protein | 1 | 2022 | 706 | 0.180 |
Why?
|
Prognosis | 8 | 2021 | 28919 | 0.180 |
Why?
|
Oncogenes | 3 | 2019 | 1244 | 0.170 |
Why?
|
Cytidine Deaminase | 1 | 2020 | 234 | 0.170 |
Why?
|
Head and Neck Neoplasms | 2 | 2022 | 2591 | 0.170 |
Why?
|
Trans-Activators | 2 | 2006 | 3053 | 0.170 |
Why?
|
Losartan | 1 | 2019 | 254 | 0.160 |
Why?
|
Phosphorylation | 4 | 2016 | 8720 | 0.160 |
Why?
|
Medical Oncology | 2 | 2020 | 2098 | 0.160 |
Why?
|
Transcriptional Activation | 3 | 2015 | 1849 | 0.160 |
Why?
|
Phenylurea Compounds | 2 | 2019 | 553 | 0.160 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2022 | 1321 | 0.160 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2016 | 745 | 0.150 |
Why?
|
Treatment Outcome | 10 | 2021 | 61932 | 0.150 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2022 | 440 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2021 | 8638 | 0.150 |
Why?
|
Radiation Tolerance | 1 | 2019 | 509 | 0.150 |
Why?
|
Japan | 1 | 2020 | 1320 | 0.150 |
Why?
|
Biopsy | 2 | 2020 | 6766 | 0.150 |
Why?
|
Proto-Oncogene Proteins | 6 | 2015 | 4677 | 0.150 |
Why?
|
Female | 29 | 2021 | 375205 | 0.150 |
Why?
|
Cytomegalovirus | 1 | 2020 | 681 | 0.140 |
Why?
|
Autopsy | 1 | 2019 | 990 | 0.140 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2020 | 877 | 0.140 |
Why?
|
Canada | 1 | 2020 | 1915 | 0.140 |
Why?
|
Mutation, Missense | 2 | 2018 | 2503 | 0.140 |
Why?
|
Standard of Care | 1 | 2018 | 497 | 0.140 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2016 | 263 | 0.140 |
Why?
|
Adenocarcinoma | 3 | 2021 | 6338 | 0.130 |
Why?
|
Middle Aged | 21 | 2021 | 213752 | 0.130 |
Why?
|
Pyridazines | 1 | 2016 | 217 | 0.130 |
Why?
|
Oxygen | 1 | 2006 | 4150 | 0.130 |
Why?
|
Antibodies | 2 | 2020 | 2431 | 0.130 |
Why?
|
Morpholines | 2 | 2014 | 572 | 0.130 |
Why?
|
Ribosomal Protein S6 | 1 | 2013 | 70 | 0.130 |
Why?
|
Aged | 17 | 2021 | 161488 | 0.130 |
Why?
|
Male | 24 | 2021 | 349524 | 0.120 |
Why?
|
Mutant Proteins | 2 | 2016 | 508 | 0.120 |
Why?
|
Exons | 1 | 2019 | 2472 | 0.120 |
Why?
|
Immunoconjugates | 1 | 2020 | 831 | 0.120 |
Why?
|
Leucovorin | 3 | 2021 | 598 | 0.120 |
Why?
|
Autocrine Communication | 1 | 2014 | 185 | 0.120 |
Why?
|
Hedgehog Proteins | 2 | 2009 | 774 | 0.120 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2011 | 2936 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2019 | 862 | 0.110 |
Why?
|
Genomics | 2 | 2018 | 5300 | 0.110 |
Why?
|
Adenosine Triphosphate | 1 | 2019 | 2203 | 0.110 |
Why?
|
Microsatellite Instability | 1 | 2015 | 664 | 0.110 |
Why?
|
HT29 Cells | 1 | 2012 | 207 | 0.110 |
Why?
|
Antigen Presentation | 1 | 2017 | 1303 | 0.110 |
Why?
|
Gene Dosage | 1 | 2016 | 1271 | 0.110 |
Why?
|
Blotting, Western | 2 | 2010 | 5456 | 0.110 |
Why?
|
Cell Growth Processes | 1 | 2012 | 413 | 0.100 |
Why?
|
Chromatin | 1 | 2022 | 2693 | 0.100 |
Why?
|
Influenza Vaccines | 1 | 1997 | 672 | 0.100 |
Why?
|
Membrane Proteins | 3 | 2015 | 8072 | 0.100 |
Why?
|
Aged, 80 and over | 8 | 2021 | 58184 | 0.100 |
Why?
|
Receptor, erbB-2 | 2 | 2018 | 2307 | 0.100 |
Why?
|
Antibodies, Monoclonal | 3 | 2017 | 9584 | 0.100 |
Why?
|
Mice, SCID | 2 | 2019 | 2835 | 0.100 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 651 | 0.100 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 2009 | 1194 | 0.100 |
Why?
|
Inhibitory Concentration 50 | 1 | 2010 | 451 | 0.100 |
Why?
|
Weight Loss | 1 | 2021 | 2450 | 0.090 |
Why?
|
Prospective Studies | 5 | 2021 | 50597 | 0.090 |
Why?
|
Fluorouracil | 3 | 2021 | 1620 | 0.090 |
Why?
|
Cohort Studies | 5 | 2021 | 39292 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2015 | 1158 | 0.090 |
Why?
|
DNA Primers | 2 | 2011 | 3002 | 0.090 |
Why?
|
DNA Damage | 1 | 2019 | 2459 | 0.090 |
Why?
|
Immunotherapy | 2 | 2021 | 4057 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11126 | 0.080 |
Why?
|
Benzamides | 1 | 2014 | 1406 | 0.080 |
Why?
|
Adult | 13 | 2021 | 211041 | 0.080 |
Why?
|
Influenza, Human | 1 | 1997 | 1344 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4254 | 0.070 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2011 | 1126 | 0.070 |
Why?
|
Disease Progression | 2 | 2020 | 13298 | 0.070 |
Why?
|
Down-Regulation | 1 | 2013 | 3093 | 0.070 |
Why?
|
Vaccination | 1 | 1997 | 2864 | 0.070 |
Why?
|
Papillomaviridae | 2 | 2022 | 1124 | 0.070 |
Why?
|
Transcription, Genetic | 3 | 2021 | 7965 | 0.070 |
Why?
|
Ireland | 3 | 2002 | 155 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 9556 | 0.070 |
Why?
|
Proteins | 1 | 2020 | 6151 | 0.070 |
Why?
|
Treatment Failure | 1 | 2011 | 2680 | 0.070 |
Why?
|
In Situ Hybridization | 1 | 2008 | 1988 | 0.070 |
Why?
|
RNA, Small Interfering | 2 | 2011 | 3645 | 0.060 |
Why?
|
DNA Methylation | 1 | 2018 | 4099 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 2865 | 0.060 |
Why?
|
Cell Proliferation | 3 | 2016 | 10803 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2021 | 8877 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1632 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2020 | 13536 | 0.060 |
Why?
|
Immunohistochemistry | 2 | 2019 | 11790 | 0.060 |
Why?
|
Genetic Variation | 1 | 2018 | 6666 | 0.060 |
Why?
|
E2F1 Transcription Factor | 1 | 2022 | 195 | 0.060 |
Why?
|
Pediatrics | 1 | 2018 | 3554 | 0.060 |
Why?
|
E2F Transcription Factors | 1 | 2022 | 274 | 0.060 |
Why?
|
Neoplasms, Experimental | 3 | 2017 | 1338 | 0.060 |
Why?
|
Mice, Transgenic | 2 | 2014 | 9927 | 0.060 |
Why?
|
Cell Line | 4 | 2020 | 16657 | 0.060 |
Why?
|
Apoptosis | 3 | 2013 | 10085 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 153 | 0.050 |
Why?
|
Molecular Structure | 1 | 2006 | 1971 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2010 | 6530 | 0.050 |
Why?
|
Lamivudine | 1 | 2022 | 341 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2019 | 6571 | 0.050 |
Why?
|
Transcription Factor AP-1 | 1 | 2022 | 332 | 0.050 |
Why?
|
Cell Compartmentation | 1 | 2021 | 428 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4941 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2022 | 2971 | 0.050 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2002 | 408 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2020 | 249 | 0.050 |
Why?
|
Enzyme Assays | 1 | 2020 | 114 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20308 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 4065 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6170 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 4926 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 11738 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 667 | 0.040 |
Why?
|
Esophagogastric Junction | 1 | 2020 | 297 | 0.040 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3507 | 0.040 |
Why?
|
Transcription Factor TFIIIA | 1 | 2016 | 25 | 0.040 |
Why?
|
Growth Substances | 1 | 2000 | 812 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39038 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2018 | 8776 | 0.040 |
Why?
|
Matrix Metalloproteinases | 1 | 2020 | 409 | 0.040 |
Why?
|
beta 2-Microglobulin | 1 | 2017 | 332 | 0.040 |
Why?
|
Chemokines | 1 | 2021 | 954 | 0.040 |
Why?
|
Young Adult | 2 | 2021 | 55940 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 114 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2021 | 787 | 0.040 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 636 | 0.040 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2021 | 844 | 0.040 |
Why?
|
Immunomodulation | 1 | 2020 | 540 | 0.040 |
Why?
|
Stromal Cells | 1 | 2021 | 1361 | 0.040 |
Why?
|
Oncogene Proteins | 1 | 2000 | 759 | 0.040 |
Why?
|
Immunity | 1 | 2021 | 957 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2017 | 681 | 0.030 |
Why?
|
DNA, Viral | 1 | 2022 | 2287 | 0.030 |
Why?
|
Outpatients | 1 | 2002 | 1349 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2019 | 1918 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 8024 | 0.030 |
Why?
|
Family Practice | 1 | 1997 | 522 | 0.030 |
Why?
|
Radiotherapy | 1 | 2021 | 1623 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2016 | 18375 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2021 | 71483 | 0.030 |
Why?
|
Models, Biological | 1 | 2011 | 9907 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2015 | 311 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6796 | 0.030 |
Why?
|
Gene Fusion | 1 | 2016 | 377 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2000 | 1421 | 0.030 |
Why?
|
Feedback, Physiological | 1 | 2016 | 480 | 0.030 |
Why?
|
Chemokine CCL5 | 1 | 2014 | 212 | 0.030 |
Why?
|
I-kappa B Proteins | 1 | 2014 | 239 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2020 | 1418 | 0.030 |
Why?
|
Organoplatinum Compounds | 1 | 2015 | 431 | 0.030 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 6068 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2019 | 3209 | 0.030 |
Why?
|
Zebrafish Proteins | 1 | 2000 | 1057 | 0.030 |
Why?
|
Codon | 1 | 2015 | 614 | 0.030 |
Why?
|
Patient Satisfaction | 2 | 2002 | 3376 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1578 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2680 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1017 | 0.030 |
Why?
|
Point Mutation | 1 | 2017 | 1656 | 0.030 |
Why?
|
Colon | 1 | 2020 | 1762 | 0.030 |
Why?
|
Camptothecin | 1 | 2015 | 555 | 0.030 |
Why?
|
Monocytes | 1 | 2021 | 2660 | 0.030 |
Why?
|
Confidence Intervals | 1 | 1997 | 2920 | 0.030 |
Why?
|
Clone Cells | 1 | 2015 | 1767 | 0.030 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2011 | 96 | 0.030 |
Why?
|
Quality Indicators, Health Care | 1 | 2002 | 1822 | 0.030 |
Why?
|
GTP Phosphohydrolases | 1 | 2015 | 515 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 2003 | 0.030 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1024 | 0.030 |
Why?
|
RNA Interference | 1 | 2020 | 3026 | 0.030 |
Why?
|
Aminopyridines | 1 | 2014 | 531 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2019 | 1597 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2020 | 4310 | 0.030 |
Why?
|
Cell Death | 1 | 2016 | 1738 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2981 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1730 | 0.020 |
Why?
|
Drug Synergism | 1 | 2014 | 1875 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2013 | 1956 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 6684 | 0.020 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2000 | 1343 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 2768 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2016 | 3879 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2040 | 0.020 |
Why?
|
Quality of Life | 2 | 2020 | 11594 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1712 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 17218 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2028 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2021 | 3417 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 7994 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3867 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2020 | 5908 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7172 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2017 | 15274 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2536 | 0.020 |
Why?
|
Quinazolines | 1 | 2014 | 1420 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 2987 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8712 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2011 | 2165 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 908 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1400 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1728 | 0.020 |
Why?
|
Genetic Testing | 1 | 2019 | 3303 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2021 | 4969 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2015 | 6293 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 1997 | 5235 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15252 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2016 | 2535 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2014 | 3179 | 0.020 |
Why?
|
Alleles | 1 | 2015 | 7090 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10362 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2427 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 20320 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 2593 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10019 | 0.010 |
Why?
|
CCN Intercellular Signaling Proteins | 1 | 2000 | 24 | 0.010 |
Why?
|
Wnt1 Protein | 1 | 2000 | 124 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 1997 | 7487 | 0.010 |
Why?
|
Base Sequence | 1 | 2011 | 13352 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22989 | 0.010 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2000 | 537 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2000 | 1777 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 84718 | 0.010 |
Why?
|
Wnt Proteins | 1 | 2000 | 727 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2000 | 1548 | 0.010 |
Why?
|
Postoperative Period | 1 | 2000 | 1843 | 0.010 |
Why?
|
beta Catenin | 1 | 2000 | 1053 | 0.010 |
Why?
|
Child | 2 | 2018 | 73636 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2000 | 4489 | 0.010 |
Why?
|
United States | 1 | 2020 | 67165 | 0.010 |
Why?
|
Transfection | 1 | 2000 | 6161 | 0.010 |
Why?
|
Binding Sites | 1 | 2000 | 6276 | 0.010 |
Why?
|
Preoperative Care | 1 | 2000 | 2357 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2000 | 6850 | 0.010 |
Why?
|
Recovery of Function | 1 | 2000 | 2950 | 0.010 |
Why?
|
Fibroblasts | 1 | 2000 | 4299 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2002 | 3885 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2000 | 14215 | 0.010 |
Why?
|
Logistic Models | 1 | 2002 | 13468 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 2000 | 18748 | 0.000 |
Why?
|
Kidney | 1 | 2000 | 6888 | 0.000 |
Why?
|
Rats | 1 | 2000 | 25094 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2000 | 12447 | 0.000 |
Why?
|